Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto® (lutetium (177Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for ...

The global Radioligand Therapy (RLT) market is poised to reach US$13 billion by 2030, expanding at a ~5% CAGR over the ...

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the ...

Marketing Novartis marketing breach sparks PMCPA call for companies to be ‘on high alert’ By Nick Paul Taylor Jun 4, 2025 9:30am PMCPA Novartis Pluvicto ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

On Monday, Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted radioligand therapy/RLT, Pluvicto (lutetium (177Lu ...

Novartis AG (NYSE:NVS) is one of the 10 Undervalued European Stocks to Invest in Now. Deutsche Bank analyst Emmanuel ...

Lantheus Holdings offers a compelling bull case, with PYLARIFY and DEFINITY driving valuation and strong growth prospects.

Among those, Novartis' (NOVN.SW) Pluvicto prostate cancer treatment generated approximately $1.4 billion in revenue last year. Another radiopharmaceutical, Lutathera, for the treatment of GEP-NET ...

The Trump administration is weighing measures that would make it more expensive for pharmaceutical companies to conduct ...

Novartis AG (NYSE:NVS) is one of the 10 Undervalued European Stocks to Invest in Now. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NYSE:NVS) on June 9, setting ...

Common isotopes include lutetium-177, actinium-225, gallium-68 (diagnostic), fluorine-18, and radium-223. The therapy combines isotopic radiance with molecular targeting-e.g., PSMA in prostate cancer ...